PHOENIX, June  30, 2026  (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ) (the &#34;Company&#34;), a biotechnology company dedicated to the advancement of regenerative therapeutics in the

CELZ

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds

CELZ raises about $4.5M via warrant exercise; five-year new warrants issued

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>PHOENIX, June  30, 2026  (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ) (the &amp;#34;Company&amp;#34;), a biotechnology company dedicated to the advancement of regenerative therapeutics in the</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Creative Medical Technology Holdings, Inc. (CELZ) announced warrant holders will immediately exercise about 2.79 million shares at $1.60, generating roughly $4.5 million in gross proceeds. In exchange, CELZ will issue new unregistered warrants for up to 5.58 million shares at $1.60, exercisable for five years after shareholder approval. Proceeds are earmarked for working capital and general corporate purposes, boosting liquidity but introducing material near-term dilution.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>CELZ warrants exercise totals 2,790,340 shares at $1.60 each.</li><li>Proceeds expected around $4.5 million before advisory fees.</li><li>New unregistered warrants for up to 5,580,680 shares at $1.60.</li><li>Closing anticipated June 30, 2026; proceeds for working capital.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Creative Medical Technology Holdings, Inc. (CELZ)</strong>: Primary party; financing transaction will dilute existing holders but funds operating needs.</li><li><strong>Roth Capital Partners (N/A)</strong>: Financial advisor for the offering; may influence deal terms and timing.</li><li><strong>The Equity Group Inc. (N/A)</strong>: Investor relations adviser; coordinates communications with investors.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. This financing event directly alters CELZ&#039;s capital structure and liquidity runway, with potential short-term dilution but improved cash position that could affect ongoing operations and clinical programs.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Dilution from new warrants could cap upside in the near term.</li><li>Approximately $4.5M cash improves liquidity but increases share count.</li><li>Closing/dilution window remains through June 30, 2026.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Aggregate warrants to exercise: 2,790,340 shares; exercise price: $1.60.</li><li>Gross proceeds expected: approximately $4.5 million before advisory fees.</li><li>New unregistered warrants: up to 5,580,680 shares at $1.60; five-year term after shareholder approval.</li><li>Closing date expected: June 30, 2026.</li><li>Proceeds to be used for working capital and general corporate purposes.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term dilution risk weighs on CELZ; monitor price action around the June 30, 2026 close.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">PHOENIX, June  30, 2026  (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc.</strong>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CELZ">CELZ</a>) (the "Company"), a biotechnology company dedicated to the advancement of regenerative therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedic, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 2,790,340 shares of common stock of the Company originally issued in October 2025, at a reduced exercise price of $1.60 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-291713). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.5 million, before deducting financial advisory fees. <br></br><br></br>Roth Capital Partners is acting as the Company’s financial advisor for this transaction.<br></br><br></br>In consideration for the immediate exercise of the existing warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 5,580,680 shares of common stock, at an exercise price of $1.60 per share upon the receipt of shareholder approval for a term of five years from the initial exercise date.<br></br><br></br>The transaction is expected to close on June 30, 2026. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. <br></br><br></br>The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "1933 Act") and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.</p>  <p align="justify">This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.<br></br><br></br><strong>About Creative Medical Technology Holdings, Inc. </strong></p>  <p align="justify">Creative Medical Technology Holdings, Inc. is a biotechnology company focused on regenerative and immunotherapy-based treatments, with programs spanning immunotherapy, endocrinology, urology, neurology, and orthopedic.</p>  <p><strong>Forward-Looking Statements </strong><br></br><br></br>This news release may contain forward-looking statements, including but not limited to comments regarding the closing of the offering and the use of proceeds therefrom, the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions, which may involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission&#39;s website at www.sec.gov.<br></br><br></br><strong>Contact: </strong></p>  <p>Creative Medical Technology Holdings, Inc.<br></br>IR@CreativeMedicalTechnology.com</p>  <p>Investor Relations:<br></br>Devin Sullivan, Managing Director<br></br>The Equity Group Inc.<br></br>dsullivan@equityny.com</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1NTAwMyM3Njg1NTI4IzIwOTYxNzQ="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YTUzZWQ2OGItNWFiOC00Y2Q3LWE0MGEtNzEwNjg1MmJiNGRlLTExMDc3NDUtMjAyNi0wNi0zMC1lbg==/tiny/Creative-Medical-Technology-Ho.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3637f1b5-adfe-4a2c-8fbe-c3cd34cdd7b1"><img src="https://ml.globenewswire.com/media/3637f1b5-adfe-4a2c-8fbe-c3cd34cdd7b1/small/celz-logo-2024-png.png" border="0" width="150" height="22" alt="Primary Logo"></img></a></p>

Creative Medical Technology Holdings, Inc. (CELZ) announced warrant holders will immediately exercise about 2.79 million shares at $1.60, generating roughly $4.5 million in gross proceeds. In exchange, CELZ will issue new unregistered warrants for up to 5.58 million shares at $1.60, exercisable for five years after shareholder approval. Proceeds are earmarked for working capital and general corporate purposes, boosting liquidity but introducing material near-term dilution.

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News